Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for immunological diseases. Its lead candidate, atacicept, is a fully humanized TACI-Fc fusion protein that binds BAFF and APRIL, administered at home as a subcutaneous injection, and is being evaluated for immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. The company is also developing MAU868, a human monoclonal antibody for BK viremia that has completed a phase 2 trial, and VT-109, a novel BAFF/APRIL dual-inhibitor BCMA molecule for B cell-mediated autoimmune diseases. Formerly known as Trucode Gene Repair, Inc., it changed its name to Vera Therapeutics, Inc. in April 2020, was incorporated in 2016, and is headquartered in Brisbane, California.
Vera Wins FDA Accelerated Approval for TRUTAKNA, Eyes Full Approval
▲
FDA Accelerated Approval of TRUTAKNA On July 7, the FDA granted accelerated approval to TRUTAKNA for IgA nephropathy, allowing Vera to sell the drug immediately. This is a major milestone that turns a pipeline story into a commercial one, boosting revenue prospects and investor confidence.
This is the single most important new event that directly answers why VERA is moving now.
▲
FDA Agreement on Earlier Kidney Function Analysis Vera reached an agreement with the FDA to analyze kidney function data earlier than planned, potentially supporting full approval. This could speed up the path to broader approval and expand the patient population, increasing the drug's market potential.
This regulatory flexibility is a key new development that de-risks and accelerates the path to full approval.
▲
Analyst Price Targets and PDUFA Anticipation Wells Fargo and LifeSci Capital reiterated Buy ratings with price targets of $70 and $90, citing atacicept's potential. Ahead of the July 7 PDUFA decision, the stock rose 6%, reflecting growing optimism about approval.
Analyst support and pre-decision momentum highlight market expectations that drive near-term price action.
◆
Intensifying Competition in IgA Nephropathy Over 25 companies are developing 30+ drugs for IgA nephropathy, with several late-stage candidates. While Vera's approval gives it a first-mover advantage, competition could pressure long-term pricing and market share.
This provides a balanced view of the competitive landscape that could cap upside despite the approval.
Q2 2026
▲3
Vera Wins FDA Accelerated Approval for TRUTAKNA, Eyes Full Approval
▲
FDA Accelerated Approval of TRUTAKNA On July 7, the FDA granted accelerated approval to TRUTAKNA for IgA nephropathy, allowing Vera to sell the drug immediately. This is a major milestone that turns a pipeline story into a commercial one, boosting revenue prospects and investor confidence.
This is the single most important new event that directly answers why VERA is moving now.
▲
FDA Agreement on Earlier Kidney Function Analysis Vera reached an agreement with the FDA to analyze kidney function data earlier than planned, potentially supporting full approval. This could speed up the path to broader approval and expand the patient population, increasing the drug's market potential.
This regulatory flexibility is a key new development that de-risks and accelerates the path to full approval.
▲
Analyst Price Targets and PDUFA Anticipation Wells Fargo and LifeSci Capital reiterated Buy ratings with price targets of $70 and $90, citing atacicept's potential. Ahead of the July 7 PDUFA decision, the stock rose 6%, reflecting growing optimism about approval.
Analyst support and pre-decision momentum highlight market expectations that drive near-term price action.
◆
Intensifying Competition in IgA Nephropathy Over 25 companies are developing 30+ drugs for IgA nephropathy, with several late-stage candidates. While Vera's approval gives it a first-mover advantage, competition could pressure long-term pricing and market share.
This provides a balanced view of the competitive landscape that could cap upside despite the approval.
News & notes movingVERA
United StatesEuropean Union
Biotech & Genomic Medicine
Vertex Builds Kidney Disease Pipeline as Povetacicept FDA Decision Looms
Vertex Pharmaceuticals is building a differentiated kidney disease franchise to diversify beyond its dominant cystic fibrosis business, with povetacicept and inaxaplin seen as significant commercial opportunities. Povetacicept, added through the approximately $4.9 billion acquisition of Alpine Immune Sciences in 2024, targets the BAFF and APRIL cytokines, and the FDA accepted a regulatory filing for its use in IgA nephropathy in June 2026, with a final decision expected on Nov. 30, 2026. If approved, povetacicept would become Vertex's first marketed nephrology product, addressing an estimated 330,000 people with IgAN in the United States and Europe and more than 1.5 million diagnosed patients globally, with analysts forecasting blockbuster sales and peak annual revenues in the multi-billion-dollar range. Inaxaplin is being developed in the phase II/III AMPLITUDE study in primary APOL1-mediated kidney disease, with enrollment complete and interim data expected in early 2027, while data from the phase II AMPLIFIED study announced earlier this week showed a 42.7% reduction in urine albumin to creatinine ratio at week 13 in patients with AMKD and modest proteinuria, and a 17.3% reduction in those with AMKD and type II diabetes. The IgA nephropathy space has grown more competitive, with the FDA already approving Otsuka's Voyxact, Vera Therapeutics' Trutakna and Novartis' Vanrafia.
Biotech & Genomic Medicine › Autoimmune & Immunology Therapeutics Competition
VRTX · Technology · Positive Povetacicept's FDA filing accepted with a Nov. 30, 2026 decision date and inaxaplin's AMPLIFIED data showing albuminuria reductions advance Vertex's kidney pipeline.
VERA · Competition · Neutral Named only as an already-approved competitor in the IgAN space (Trutakna), with no new development of its own.
Vera Therapeutics Says TRUTAKNA Met All Phase III Endpoints in ORIGIN 3 Trial
Vera Therapeutics reported that TRUTAKNA met all prespecified endpoints in the final Phase III ORIGIN 3 trial for IgA nephropathy. The company said the study showed prevention of disease progression and stabilization of kidney function alongside a favorable safety profile. Management plans to seek full FDA approval for TRUTAKNA later in 2026 through a supplemental biologics license application. Early launch signs, with more than 350 patient start forms in ten weeks, point to real demand, though Vera is coming off a very low revenue base. A practical checkpoint will be how prescription trends and patient start forms look by the time Vera files its supplemental BLA in the fourth quarter of 2026.
VERA · Technology · Positive TRUTAKNA met all prespecified Phase III ORIGIN 3 endpoints in IgA nephropathy with favorable safety, supporting a full FDA approval filing.
VERA · Demand · Positive More than 350 patient start forms in ten weeks point to real early demand for TRUTAKNA.
Vera Therapeutics Wins FDA Accelerated Approval for TRUTAKNA in Primary IgA Nephropathy
Vera Therapeutics has received accelerated approval from the U.S. Food and Drug Administration for TRUTAKNA to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. The approved dose is 150 milligrams injected subcutaneously once weekly via an autoinjector. In a prespecified interim analysis of the ongoing ORIGIN 3 trial, TRUTAKNA achieved a 46 percent reduction in proteinuria from baseline and a 42 percent reduction compared to placebo at 36 weeks. Continued approval depends on verification of clinical benefit in the same trial, with results on kidney function expected in the third quarter of 2026. TRUTAKNA enters a competitive market that includes Filspari, Tarpeyo, Fabhalta, Vanrafia, and Voyxact.
Scilex, Vera Therapeutics rise premarket; Strategy gains
Scilex Holding jumped 7% in premarket trading after announcing a binding term sheet for a proposed $100 million strategic investment from Kazakhstan-based private investment group iHolding Group LLP. Vera Therapeutics gained 6% ahead of its July 7 Prescription Drug User Fee Act decision for atacicept, its investigational treatment for IgA nephropathy. Solaris Energy Infrastructure rose 3.9% after Wolfe Research initiated coverage with an Outperform rating and a $120 price target, and the company also announced the acquisition of power generation services provider Global Energy Services Alliance for approximately $55 million in cash and stock. Strategy climbed 3.4% as investors continued to digest the company's newly adopted Digital Credit Capital Framework, which authorizes the selective monetization of up to $1.25 billion of its Bitcoin holdings to bolster liquidity, fund preferred dividends and support share repurchases.
Digital Finance & Tokenization › Bitcoin / Crypto Treasury & Store-of-Value Proxies Capital
Energy Transition & Power Demand › Grid, Transmission & Power Equipment ▲Competition
SCLX · Capital · Positive Scilex announced a binding term sheet for a $100 million strategic investment from iHolding Group.
SEI · Capital · Positive Solaris Energy Infrastructure received an Outperform rating from Wolfe Research and announced an acquisition.
VERA · Regulation · Positive Vera Therapeutics is approaching a PDUFA decision for atacicept, a regulatory milestone.
MSTR · Capital · Neutral Strategy (MicroStrategy) adopted a Digital Credit Capital Framework to monetize Bitcoin holdings, but impact is unclear as it's a financial strategy move.
FDA Progress Could Send Vera Therapeutics Stock Soaring
Wells Fargo reiterated a Buy rating on Vera Therapeutics with a $70 price target, while LifeSci Capital maintained a Buy rating and set a $90 target, citing strong potential for its lead drug atacicept in treating IgA nephropathy. The company's June 2, 2026 agreement with the FDA allows earlier analysis of kidney function data from its Phase III ORIGIN 3 study, and positive results could enable a full approval application in the fourth quarter of 2026. Atacicept is already under priority review for accelerated approval, and broader patient eligibility could expand its market opportunity.
IgA Nephropathy Clinical Trial Space Intensifies with 25+ Companies in Active Development
The IgA nephropathy clinical trial space is intensifying, with more than 25 companies actively developing over 30 pipeline drugs, according to a new report from DelveInsight. Key players include Haisco Pharmaceutical Group, Novartis, Vertex Pharmaceuticals, Biogen, Vera Therapeutics, AstraZeneca, Roche, Ionis Pharmaceuticals, Takeda, Arrowhead Pharmaceuticals, and others. Promising therapies in various trial phases include HSK39297, Zigakibart, Povetacicept, Felzartamab, Atacicept, ULTOMIRIS, Sefaxersen, TAK-079, ARO-C3, NM8074, WAL0921, KP104, PS-002, BHV-1400, CM313, NTQ5082, RNK288, and IFX 301. Approximately 12 or more drugs are in late-stage development, targeting mechanisms such as Complement Factor B inhibition, BAFF and APRIL antagonism, antibody-dependent cell cytotoxicity, Gd-IgA1 degradation, RNA interference, and CD38 antagonism. Recent milestones include positive Phase III data for Povetacicept and Atacicept, and publication of telitacicept results in the New England Journal of Medicine.
Three Biotech Firms Face Major Catalysts in Coming Months
Three biotech companies are approaching significant catalysts that could reshape their futures. Vera Therapeutics is preparing a Biologics License Application for atacicept, an investigational drug for IgA nephropathy, with an accelerated timeline following FDA alignment on a revised analysis plan expected in the third quarter. Krystal Biotech, which already markets the first gene therapy approved for a skin condition, anticipates top-line results from its KB803 corneal abrasion trial by year-end and a registrational data readout for KB801 in 2026. ADMA Biologics, which has multiple marketed products and reported 28% year-over-year revenue growth from ASCENIV last quarter, is advancing SG-001, an investigative hyperimmune globulin candidate for pneumococcal disease, while also benefiting from margin expansion driven by new manufacturing efficiencies.
Vera Therapeutics Reaches FDA Agreement on Accelerated Atacicept Approval Timeline
Vera Therapeutics reached an agreement with the U.S. Food and Drug Administration on an accelerated timeline for its ORIGIN 3 eGFR analysis plan to support full regulatory approval of atacicept for adults with IgA nephropathy. The company expects to release eGFR findings in the third quarter of 2026 and plans to file a supplemental Biologics License Application in the fourth quarter of 2026, contingent on the data. The modified regulatory approach was supported by past eGFR data from the ORIGIN Phase 2b clinical trial. Founder and CEO Marshall Fordyce noted the medication's potential to be the first licensed treatment targeting both BAFF and APRIL for adult IgAN patients.
USA